

Accelerating Population Proteomics



somalogic

SomaLogic is committed to:



Proteomic excellence:

Delivering the most comprehensive, reliable and trusted proteomic platforms for the global biobank community, supporting discovery of new targets and biomarkers to improve human health.



Clinical translation:

Supporting the translation of biobank discoveries to advance new drug candidates and accelerate clinical trials.



Business partnership:

Providing innovative, high-quality life science tools to the research community while creating long-term collaborative relationships.

Why choose the SomaScan Platform for population proteomics?



Unmatched proteome coverage for deeper insights

Profile 11,000 protein measurements for the most comprehensive view of the human proteome and the most insights for biomarker discovery and drug target development.



Highest scalability and reproducibility

Designed to support longitudinal and multi-site studies, the SomaScan™ Assay delivers consistent, high-throughput results with about 5% inter-assay CVs and standardized calibrators.



Cost-effective and accessible

SomaLogic partners with global biobank stakeholders to deliver affordable large-scale studies, ensuring high-impact population health insights.



More efficient clinical trials

SomaSignal™ Tests (RUO) can be used retrospectively and prospectively to help accelerate trial success and clinical research program decision-making.



Consistent, reproducible results across sites

Achieve reliable and reproducible results, whether running samples at our CLIA-certified Service Lab or at an Authorized Site worldwide.



Antibody alternative for singleplex affinity assays

Single SOMAmer™ Reagents – the high-performance reagents behind the SomaScan Assay – are now available as an antibody alternative. Ready for use in ELISA and pull-down workflows, their small size, exceptional stability and reduced nonspecific binding make them an ideal solution when traditional antibodies fall short.




Pre-analytical sample quality assessments

Prevent experimental failure and unnecessary costs by knowing which samples have degraded, the cause and extent, and how to manage sample variability. PAV tests are currently available for the SomaScan 7K Assay.

More biology to discover: Find the unexpected


With access to 11,000 protein measurements, the SomaScan Assay enables researchers to uncover novel biomarkers and biological pathways, insights often missed by lower-plex platforms.

In a study of over 15,000 participants, the SomaScan Assay identified more than 3,300 proteins predictive of breast cancer risk, nearly 10 times more than lower-plex platforms, even with fewer samples. These included both known drug targets and previously unrecognized proteins that may point to new disease mechanisms, novel drug targets or early diagnostic markers.



Number of proteins predicting cancer risk

EPIC SomaScan 7K Assay in 15,000 participants, UK Biobank high-plex antibody assay in 54,000 participants all $p < 0.1$, FDR corrected



SomaLogic is the leader in population proteomics, supporting a large number of biobank studies worldwide



SL00000823 Rev 4 022026

Accelerating Population Proteomics Flyer

For Research Use Only. Not for use in diagnostic procedures.

Any other trademarks are the sole property of their respective owners. ©2026 SomaLogic Operating Co., Inc. All rights reserved.

View data discovered by biobanks using the SomaScan Platform

